Form 4 for IKT Inhibikase Therapeutics, Inc.
Accepted 2022-01-04 00:00:00 ET · period of report 2022-01-03 · accession 0001104659-22-001168 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-01-04 | 2022-01-03 | IKT | Werner Milton H. | Pres, CEO, Dir, 10% | M - OptEx | $2.02 | +21.9K | 5.32M | +0.4% | +$44.1K |
| D | 2022-01-04 | 2022-01-03 | IKT | Werner Milton H. | Pres, CEO, Dir, 10% | M - OptEx | $0.00 | -21.9K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-01-03 | M | A | 21,853 | $2.02 | 5,315,433 | D | — | — | |
| 2 | Derivative | Stock Option (right to buy) | 2022-01-03 | M | D | 21,853 | $0.00 | 0 | D | $2.02 · — to 2025-03-01 | 21,853 Common Stock | (F1) The option vested in twelve equal monthly installments beginning on March 1, 2015. |